Metachronous (MBC) and synchronous bilateral breast tumors (SBC) are mostly distinct primaries, whereas paired primaries and their local recurrences (LRC) share a common origin. Intra-pair gene expression variability in MBC, SBC, and LRC derives from time/tumor microenvironment-related and tumor genetic background-related factors and pairs represents an ideal model for trying to dissect tumor-related from microenvironment-related variability. Pairs of tumors derived from women with SBC (n = 18), MBC (n = 11), and LRC (n = 10) undergoing local-regional treatment were profiled for gene expression; similarity between pairs was measured using an intraclass correlation coefficient (ICC) computed for each gene and compared using analysis of varia...
Purpose: The majority of patients with early-stage breast cancer are treated with breast-conserving ...
PURPOSE: The majority of patients with early-stage breast cancer are treated with breast-conserving ...
Breast cancer is the 2nd most common cancer globally with nearly 1.7 million new cases of all cancer...
The last decade has revealed fundamental new insight into the existence of intrinsic molecular subcl...
The nature of genetic alterations in bilateral breast cancer (BBC) associated with the distinctive d...
The original publication can be found at www.springerlink.comBilateral breast cancers that develop a...
International audienceSynchronous bilateral breast cancer (sBBC) occurs after both breasts have been...
Metastasis is the main cause of cancer patient deaths and remains a poorly characterized process. It...
The molecular pathogenesis of various categories of breast cancer (BC) has been well described, but ...
Abstract Background Molecular classification of tumour clonality is currently not evaluated in multi...
The clonal origin of multiple tumors in the same individual has long been debated. The main aim of t...
<div><p>Background</p><p>Synchronous tumors can be independent primary tumors or a primary-metastati...
BackgroundHow to evaluate the prognosis and develop overall treatment strategies of metachronous bil...
BackgroundHow to evaluate the prognosis and develop overall treatment strategies of metachronous bil...
ABSTRACT: BACKGROUND: Today, no objective criteria exist to differentiate between individual primary...
Purpose: The majority of patients with early-stage breast cancer are treated with breast-conserving ...
PURPOSE: The majority of patients with early-stage breast cancer are treated with breast-conserving ...
Breast cancer is the 2nd most common cancer globally with nearly 1.7 million new cases of all cancer...
The last decade has revealed fundamental new insight into the existence of intrinsic molecular subcl...
The nature of genetic alterations in bilateral breast cancer (BBC) associated with the distinctive d...
The original publication can be found at www.springerlink.comBilateral breast cancers that develop a...
International audienceSynchronous bilateral breast cancer (sBBC) occurs after both breasts have been...
Metastasis is the main cause of cancer patient deaths and remains a poorly characterized process. It...
The molecular pathogenesis of various categories of breast cancer (BC) has been well described, but ...
Abstract Background Molecular classification of tumour clonality is currently not evaluated in multi...
The clonal origin of multiple tumors in the same individual has long been debated. The main aim of t...
<div><p>Background</p><p>Synchronous tumors can be independent primary tumors or a primary-metastati...
BackgroundHow to evaluate the prognosis and develop overall treatment strategies of metachronous bil...
BackgroundHow to evaluate the prognosis and develop overall treatment strategies of metachronous bil...
ABSTRACT: BACKGROUND: Today, no objective criteria exist to differentiate between individual primary...
Purpose: The majority of patients with early-stage breast cancer are treated with breast-conserving ...
PURPOSE: The majority of patients with early-stage breast cancer are treated with breast-conserving ...
Breast cancer is the 2nd most common cancer globally with nearly 1.7 million new cases of all cancer...